Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Starts China Phase III Trial of PD-1 Drug in Squamous NSCLC

publication date: Aug 9, 2018

BeiGene, a Beijing oncology biopharma, has dosed the first patient in a China Phase III trial of its PD-1 antibody as a first-line treatment for lung cancer. According to BeiGene's count, the trial is the ninth indication for the PD-1 candidate, tislelizumab. The latest trial combines tislelizumab with chemotherapy to treat China patients with squamous non-small cell lung cancer. One year ago, BeiGene out-licensed global rights (ex-Asia) for tislelizumab to Celgene in a $1.4 billion agreement. More details...

Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: CLGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.